Peroxisome Proliferator-Activated Receptor (PPAR) Agonist - Pipeline Insight, 2018 - ResearchAndMarkets.com

DUBLIN--()--The "Peroxisome Proliferator-Activated Receptor (PPAR) Agonist - Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

Peroxisome Proliferator-Activated Receptor (PPAR) Agonist - Pipeline Insight, 2018 report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Peroxisome Proliferator-Activated Receptor (PPAR) Agonist development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Peroxisome Proliferator-Activated Receptor (PPAR) Agonist - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Key Topics Covered:

1. Report Introduction

2. Peroxisome Proliferator-Activated Receptor (PPAR) Agonist - Overview

3. Pipeline Therapeutics

4. Comparative Analysis

5. Peroxisome Proliferator-Activated Receptor (PPAR) Agonist Pipeline Products in Clinical Stages

6. Peroxisome Proliferator-Activated Receptor (PPAR) Agonist Pipeline Products in Non-clinical Stages

7. Therapeutic Assessment: Active Products

8. Inactive Pipeline Products

Companies Mentioned
  • Esperion Therapeutics
  • Streki
  • DARA BioSciences
  • T3D Therapeutics
  • Ligand Pharmaceuticals
  • Minoryx Therapeutics
  • Biophytis
  • Genfit
  • sanofi-aventis
  • Omeros Corporation

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/97dvp3/peroxisome?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Endocrine and Metabolic Disorders Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Endocrine and Metabolic Disorders Drugs